<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:xmi="http://www.omg.org/XMI" xmlns:pos="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/pos.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmlns:cas="http:///uima/cas.ecore" xmlns:tweet="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/pos/tweet.ecore" xmlns:type8="http:///org/apache/uima/ruta/type.ecore" xmlns:morph="http:///de/tudarmstadt/ukp/dkpro/core/api/lexmorph/type/morph.ecore" xmlns:dependency="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/dependency.ecore" xmlns:type6="http:///de/tudarmstadt/ukp/dkpro/core/api/semantics/type.ecore" xmlns:type9="http:///org/apache/uima/trials/type.ecore" xmlns:noNamespace="http:///uima/noNamespace.ecore" xmlns:type="http:///de/tudarmstadt/ukp/dkpro/core/api/anomaly/type.ecore" xmlns:type7="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type.ecore" xmlns:type3="http:///de/tudarmstadt/ukp/dkpro/core/api/metadata/type.ecore" xmlns:type4="http:///de/tudarmstadt/ukp/dkpro/core/api/ner/type.ecore" xmlns:type5="http:///de/tudarmstadt/ukp/dkpro/core/api/segmentation/type.ecore" xmlns:type2="http:///de/tudarmstadt/ukp/dkpro/core/api/coref/type.ecore" xmlns:constituent="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/constituent.ecore" xmlns:chunk="http:///de/tudarmstadt/ukp/dkpro/core/api/syntax/type/chunk.ecore" xmi:version="2.0"><cas:NULL xmi:id="0"/><tcas:DocumentAnnotation xmi:id="2" sofa="1" begin="0" end="2390" language="x-unspecified"/><type9:ORR xmi:id="3" sofa="1" begin="1470" end="1473"/><type9:ORR xmi:id="4" sofa="1" begin="1526" end="1531"/><type9:ORR xmi:id="5" sofa="1" begin="2003" end="2008"/><type9:ORR xmi:id="14" sofa="1" begin="2147" end="2153"/><type9:ORR xmi:id="12" sofa="1" begin="2214" end="2217"/><type9:OSMean xmi:id="6" sofa="1" begin="1661" end="1671"/><type9:OSMean xmi:id="7" sofa="1" begin="2018" end="2026"/><type9:OSMean xmi:id="13" sofa="1" begin="2222" end="2234"/><type9:OSTime xmi:id="8" sofa="1" begin="1677" end="1685"/><type9:OSRate xmi:id="9" sofa="1" begin="1704" end="1709"/><type9:PFSMean xmi:id="10" sofa="1" begin="1759" end="1768"/><type9:PFSMean xmi:id="11" sofa="1" begin="2038" end="2046"/><cas:Sofa xmi:id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="The purpose of the study was to evaluate the effectiveness in terms of response&#13;&#10;rates, toxicity and survival of the combination chemotherapy regimen cisplatin&#13;&#10;and epidoxorubicin (epirubicin) including medroxyprogesterone acetate (MPA),&#13;&#10;recombinant IL-2 (rIL-2) and antioxidants in patients with advanced (stage&#13;&#10;IIIB-IV) non-small cell lung cancer (NSCLC). Thirty-three chemotherapy-naive&#13;&#10;patients with NSCLC were enrolled in the study and 30 of them were evaluable. The&#13;&#10;mean age of the patients was 61 years. Twenty (66.7%) out of 30 patients were&#13;&#10;&gt;or=60 years, and 5 (16.7%) patients were &gt;or=70 years. The ECOG performance&#13;&#10;status was 0 to 1 in 30 patients and 2 in 3 patients. Twenty-six patients (78.8%)&#13;&#10;had stage IIIB disease and 7 (21.2%) had stage IV; histology was mainly squamous &#13;&#10;cell carcinoma (72.7%). The treatment consisted of cisplatin 40 mg/m2/week and&#13;&#10;epirubicin 40 mg/m2/week both intravenously on day 1, rIL-2 1.8 MIU/day&#13;&#10;subcutaneously, MPA 1 g/day orally, alpha-lipoic acid 300 mg/day orally and&#13;&#10;N-acetyl cysteine 1.8 g/day orally. The treatment was administered for 6 weeks.&#13;&#10;Patients with a complete response (CR), partial response (PR) or stable disease&#13;&#10;(SD) continued the treatment, according to response re-evaluation, until 15&#13;&#10;weeks. The present study reports the results of 6, 9, 12 and 15-week treatment.&#13;&#10;After 6 weeks, 30 patients were assessable for response: no CR was observed, a PR&#13;&#10;was achieved in 15 patients (50%; ORR 50%). After 15 weeks, 1 CR and 8 PR were&#13;&#10;observed (ORR 30.0%). The median follow-up period was 13 months. The median&#13;&#10;duration of response was 9 months. The median overall survival (OS) was 15&#13;&#10;months. The one-year survival rate was 55.8%. The median progression-free&#13;&#10;survival (PFS) was 10 months. The toxicity was, as expected, mainly hematologic: &#13;&#10;neutropenia was the most significant symptom. The non-hematologic toxicity was&#13;&#10;quite low. Therefore, the treatment's toxicity was quite acceptable. There was no&#13;&#10;toxic death. The 30.0% ORR, the 15 month OS and the 10 month PFS obtained in this&#13;&#10;study are comparable with those observed with cisplatin plus epirubicin (ORR&#13;&#10;39-54%) in phase II studies and in a previous phase III study (ORR 33%, OS 10.5&#13;&#10;months). Moreover, the toxicity was acceptable and it was mainly hematologic.&#13;&#10;Serum levels of proinflammatory cytokines significantly decreased after&#13;&#10;treatment."/><cas:View sofa="1" members="2 3 4 5 14 12 6 7 13 8 9 10 11"/></xmi:XMI>